Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | President and CEO | April 13, 2022 | April 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date April 13, 2022 · Filed April 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.11 · Expires 2032-04-13 | Direct | 240,000 |
Reported balance
After 2022-04-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-04-13 · Grant · Acquired 240,000 · Balance 240,000 F1: The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2022 Filed Apr 15, 2022 19:46 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001104659-22-046440 · tm2212851-1_4seq1.xml · derivative · entry 1 Varnum Brian · CIK 0001774252 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2032-04-13 F1 · derivative.exercise_date: The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 21:23 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001104659-21-099565 · tm2124032-2_4seq1.xml · derivative · entry 1 Varnum Brian · CIK 0001774252 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-08-02 F1 · derivative.exercise_date: The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 23:35 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001104659-21-042631 · tm2111079-4_4seq1.xml · derivative · entry 1 Varnum Brian · CIK 0001774252 · President and CDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2031-03-25 F1 · derivative.exercise_date: The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 21:06 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001104659-20-133633 · tm2038059-4_4seq1.xml · derivative · entry 1 Varnum Brian · CIK 0001774252 · President and CDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| May 22, 2019 Filed May 25, 2019 01:30 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 298,724 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001144204-19-028255 · tv522361_4.xml · derivative · entry 1 Varnum Brian · CIK 0001774252 · President and CDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,724 Underlying: Common Stock · 298,724 shares Expires 2029-05-22 F1 · derivative.exercise_date: The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each annual anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.